JP2023523568A5 - - Google Patents
Info
- Publication number
- JP2023523568A5 JP2023523568A5 JP2022562528A JP2022562528A JP2023523568A5 JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5 JP 2022562528 A JP2022562528 A JP 2022562528A JP 2022562528 A JP2022562528 A JP 2022562528A JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- subject
- level
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009400P | 2020-04-13 | 2020-04-13 | |
| US63/009,400 | 2020-04-13 | ||
| PCT/US2021/026816 WO2021211418A1 (en) | 2020-04-13 | 2021-04-12 | Methods for treating anemia using an actriib ligand trap and fedratinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523568A JP2023523568A (ja) | 2023-06-06 |
| JP2023523568A5 true JP2023523568A5 (https=) | 2024-04-05 |
Family
ID=78085002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562528A Pending JP2023523568A (ja) | 2020-04-13 | 2021-04-12 | ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181690A1 (https=) |
| EP (1) | EP4135736A4 (https=) |
| JP (1) | JP2023523568A (https=) |
| KR (1) | KR20230003502A (https=) |
| CN (1) | CN115427056A (https=) |
| AU (1) | AU2021256419A1 (https=) |
| BR (1) | BR112022020628A2 (https=) |
| IL (1) | IL297258A (https=) |
| MX (1) | MX2022012610A (https=) |
| WO (1) | WO2021211418A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| CA2983440C (en) * | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| MA45811A (fr) * | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| WO2018053142A2 (en) * | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| PL3638243T3 (pl) * | 2017-06-14 | 2025-02-10 | Celgene Corporation | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
| WO2020041466A1 (en) * | 2018-08-21 | 2020-02-27 | Sierra Oncology, Inc. | Platelet count-agnostic methods of treating myelofibrosis |
| KR20250134004A (ko) * | 2018-09-25 | 2025-09-09 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
-
2021
- 2021-04-12 US US17/995,915 patent/US20230181690A1/en active Pending
- 2021-04-12 JP JP2022562528A patent/JP2023523568A/ja active Pending
- 2021-04-12 BR BR112022020628A patent/BR112022020628A2/pt unknown
- 2021-04-12 KR KR1020227039230A patent/KR20230003502A/ko active Pending
- 2021-04-12 MX MX2022012610A patent/MX2022012610A/es unknown
- 2021-04-12 WO PCT/US2021/026816 patent/WO2021211418A1/en not_active Ceased
- 2021-04-12 EP EP21787716.6A patent/EP4135736A4/en active Pending
- 2021-04-12 CN CN202180028593.0A patent/CN115427056A/zh active Pending
- 2021-04-12 IL IL297258A patent/IL297258A/en unknown
- 2021-04-12 AU AU2021256419A patent/AU2021256419A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11827706B2 (en) | Anti-B7-H1 antibodies for treating tumors | |
| AU2005240082B2 (en) | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients | |
| CN109661241A (zh) | 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法 | |
| JP2020524139A5 (https=) | ||
| JP2016505240A5 (https=) | ||
| TWI877239B (zh) | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 | |
| JP2023523568A5 (https=) | ||
| KR20210046716A (ko) | 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료 | |
| JP2023526590A5 (https=) | ||
| JPH10510553A (ja) | 多外傷後の多発性臓器不全の防止のための及び体外血液循環後の急性臓器損傷の防止のための抗−セレクチン抗体 | |
| US20240226168A1 (en) | Engineered nk cells and uses thereof | |
| CN111533782A (zh) | 一种靶向免疫检查点lag-3的活性多肽及其应用 | |
| US20240368271A1 (en) | Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals | |
| WO2018209017A1 (en) | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor | |
| CN113117072A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| US20240150469A1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| WO2024037594A1 (en) | Combination treatment with orelabrutinib and tafasitamab | |
| EP3008089A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
| US11324774B2 (en) | Compositions of oral alkaline salts and metabolic acid inducers and uses thereof | |
| RU2802962C2 (ru) | Композиции и способы лечения рака печени | |
| CN121693348A (zh) | 肿瘤联合治疗及使用方法 | |
| CN118946366A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| CN115920035A (zh) | 一种药物制剂及其在治疗肝癌中的应用 | |
| WO2022250070A1 (ja) | ウベニメクスと免疫チェックポイント阻害剤の併用 |